Barbara Ferstl

811 total citations
13 papers, 316 citations indexed

About

Barbara Ferstl is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Barbara Ferstl has authored 13 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Oncology and 5 papers in Genetics. Recurrent topics in Barbara Ferstl's work include Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Peptidase Inhibition and Analysis (4 papers). Barbara Ferstl is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Peptidase Inhibition and Analysis (4 papers). Barbara Ferstl collaborates with scholars based in Germany, Austria and Switzerland. Barbara Ferstl's co-authors include Hermine Agis, Hartmut Goldschmidt, Christoph Röllig, Christian Peschel, Hermann Einsele, Marc S. Raab, Katja Weisel, Monika Engelhardt, Manik Chatterjee and Igor Wolfgang Blau and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Barbara Ferstl

13 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Ferstl Germany	10	150	112	105	92	68	13	316
Ron MacFarland United States	9	287 1.9×	301 2.7×	126 1.2×	252 2.7×	79 1.2×	10	573
Thomas Rückrich Germany	7	116 0.8×	85 0.8×	257 2.4×	56 0.6×	31 0.5×	8	357
Hannah R. Robinson United States	8	24 0.2×	61 0.5×	93 0.9×	128 1.4×	54 0.8×	17	410
Tatjana Spasokoukotskaja Sweden	11	79 0.5×	154 1.4×	299 2.8×	32 0.3×	15 0.2×	17	516
Makoto Takishita Japan	7	101 0.7×	73 0.7×	117 1.1×	132 1.4×	54 0.8×	11	344
Jean-Pierre Marie France	6	143 1.0×	93 0.8×	94 0.9×	82 0.9×	35 0.5×	6	292
Britt Thuresson Sweden	12	276 1.8×	40 0.4×	102 1.0×	82 0.9×	9 0.1×	23	412
Massimiliano Pascuccio Italy	6	54 0.4×	16 0.1×	99 0.9×	140 1.5×	128 1.9×	9	314
Kristina Drott Sweden	13	33 0.2×	100 0.9×	196 1.9×	109 1.2×	15 0.2×	24	338
Monica Jones United States	13	181 1.2×	274 2.4×	52 0.5×	533 5.8×	25 0.4×	21	654

Countries citing papers authored by Barbara Ferstl

Since Specialization

Citations

This map shows the geographic impact of Barbara Ferstl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Ferstl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Ferstl more than expected).

Fields of papers citing papers by Barbara Ferstl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Ferstl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Ferstl. The network helps show where Barbara Ferstl may publish in the future.

Co-authorship network of co-authors of Barbara Ferstl

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Ferstl. A scholar is included among the top collaborators of Barbara Ferstl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Ferstl. Barbara Ferstl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Schliep, Stefan, et al.. (2022). Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement. Current Oncology. 29(5). 2909–2919. 12 indexed citations

Raab, Marc S., Monika Engelhardt, Antje Blank, et al.. (2020). MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. The Lancet Haematology. 7(5). e381–e394. 68 indexed citations

Liebers, Nora, Tobias Roider, Isabella Haberbosch, et al.. (2019). BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia. 34(5). 1454–1457. 17 indexed citations

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2018). MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study. Blood. 132(Supplement 1). 153–153. 9 indexed citations

Chatterjee, Manik, Marc S. Raab, Hartmut Goldschmidt, et al.. (2017). A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e61–e61. 20 indexed citations

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2017). MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study.. Journal of Clinical Oncology. 35(15_suppl). 8024–8024. 3 indexed citations

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2016). MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.. Journal of Clinical Oncology. 34(15_suppl). 8012–8012. 16 indexed citations

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2016). A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 128(22). 1152–1152. 32 indexed citations

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2015). Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma. Blood. 126(23). 3035–3035. 7 indexed citations

10.

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2015). A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 15. e80–e80. 4 indexed citations

11.

Raab, Marc S., Hartmut Goldschmidt, Hermine Agis, et al.. (2015). A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).. Journal of Clinical Oncology. 33(15_suppl). 8574–8574. 27 indexed citations

12.

Harrer, Ellen G., Michael Bäuerle, Barbara Ferstl, et al.. (2005). Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1 Nef-Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption. Antiviral Therapy. 10(2). 285–300. 86 indexed citations

13.

Ferstl, Barbara, et al.. (2004). Allele-specific quantification of HLA-DQB1 gene expression by real-time reverse transcriptase-polymerase chain reaction. Genes and Immunity. 5(5). 405–416. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact